Zusduri is a prescription medicine made by UroGen. Its active ingredient is mitomycin, a chemotherapy medicine that has been used in the bladder for many years. In Zusduri, the mitomycin is mixed with a special gel.
The medicine is kept cold so it stays liquid while it goes into your bladder. When it warms up to body temperature, it turns into a soft gel. The gel stays in your bladder and slowly dissolves into your urine over several hours. This keeps the medicine in contact with the bladder lining for a longer time.
Mitomycin works by blocking cancer cells from copying their DNA, so they cannot grow and divide. Because the medicine is placed right into the bladder, very little of it reaches the rest of your body.
FDA Approval
The U.S. Food and Drug Administration (FDA) approved Zusduri in June 2025 for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This means low-grade tumors on the inside lining of the bladder that have come back after earlier surgery.